Below is a summary of clinical outcomes associated with some commonly prescribed GLP-1 medications: In a 68-week trial, participants receiving semaglutide experienced an average weight reduction of approximately 14.9%, compared to 2.4% in the placebo group
2019 Nov 5;9(1):16073 2 Spence JD, Thornton T, Muir AD, Westcott ND
Long-term treatment may continue for years with ongoing monitoring, though some patients may eventually discontinue with appropriate support for weight maintenance
Preclinical studies showed preferential reduction of abdominal and visceral adipose tissue, suggesting favorable body composition changes even when total weight loss is moderate
Several studies have examined the effectiveness of supplemental carnitine in the management of cardiac ischemia (restriction of blood flow to the heart) and peripheral arterial disease (whose most important symptom is poor circulation in the legs, known as intermittent claudication)